Exact Sciences Q1 2021 Earnings Report
Key Takeaways
Exact Sciences reported a revenue of $402.1 million for the first quarter ended March 31, 2021, representing a 16% increase compared to the $347.8 million reported for the same period in 2020. The company's screening and precision oncology segments showed growth, and they anticipate revenue of $1,690-$1,735 million during 2021.
Total revenue was $402.1 million, an increase of 16 percent.
Screening revenue was $240.3 million, an increase of 10 percent.
Precision Oncology revenue was $129.4 million, an increase of 1 percent.
COVID-19 testing revenue was $32.3 million.
Exact Sciences
Exact Sciences
Exact Sciences Revenue by Segment
Forward Guidance
The company anticipates revenue of $1,690-$1,735 million during 2021, including Screening revenue of $1,125-$1,150 million, Precision Oncology revenue of $515-$525 million, and COVID-19 testing revenue of $50-$60 million.
Revenue & Expenses
Visualization of income flow from segment revenue to net income